Zacks Research Increases Earnings Estimates for Hologic

Key Points

• Zacks Research has raised its FY2025 earnings per share estimate for Hologic to $4.23, slightly up from the previous estimate of $4.22.
• Hologic received upgrades from several brokerages, including Argus and Citigroup, both now rating the stock as a "buy" with target prices set at $80.00.
• The company's stock currently has an average rating of "Moderate Buy" with a consensus target price of $78.00, amid increasing interest from institutional investors.

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Zacks Research raised their FY2025 earnings per share (EPS) estimates for Hologic in a research note issued to investors on Wednesday, September 17th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings per share of $4.23 for the year, up from their prior forecast of $4.22. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's Q4 2025 earnings at $1.09 EPS, Q1 2026 earnings at $1.06 EPS, Q4 2026 earnings at $1.14 EPS and Q2 2027 earnings at $1.19 EPS.

A number of other research firms also recently issued reports on HOLX. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and raised their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Evercore ISI raised their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Wall Street Zen cut Hologic from a "buy" rating to a "hold" rating in a research report on Monday, September 15th. Argus lifted their price target on Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research report on Friday. Finally, Mizuho set a $75.00 price target on Hologic in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.38.

Hologic Stock Performance

NASDAQ:HOLX traded down $1.94 during trading hours on Thursday, reaching $66.33. The stock had a trading volume of 8,515,121 shares, compared to its average volume of 1,762,988. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The stock has a 50 day simple moving average of $66.47 and a 200 day simple moving average of $62.75. Hologic has a 12-month low of $51.90 and a 12-month high of $84.39. The stock has a market cap of $14.75 billion, a P/E ratio of 27.52, a price-to-earnings-growth ratio of 2.40 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the business posted $1.06 earnings per share. The business's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Chung Wu Investment Group LLC bought a new stake in Hologic during the second quarter worth about $26,000. Caitong International Asset Management Co. Ltd boosted its holdings in Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 273 shares during the period. Loomis Sayles & Co. L P purchased a new stake in Hologic in the 2nd quarter worth approximately $33,000. Zions Bancorporation National Association UT purchased a new stake in Hologic in the 1st quarter worth approximately $34,000. Finally, Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after buying an additional 436 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.